BioCentury
ARTICLE | Strategy

CAT catches a change artist

March 4, 2002 8:00 AM UTC

Cambridge Antibody Technology Group plc has defied conventional wisdom by choosing a new CEO with no experience in moving drugs through the clinic to market. Instead, the antibody company last week named Peter Chambre, who was COO at Celera Genomics Group, because of his expertise in helping companies make the transition from one stage of development to another.

"Both the board and senior company management were unanimous in selecting Peter," said John Aston, CFO at Cambridge Antibody (LSE:CAT; CATG, Melbourn, U.K.). Chambre will start work in early April, when founder and CEO David Chiswell leaves...